1 The systemic and regional haemodynamic effects of the potassium channel activator EMD 52692 or its solvent were investigated after intravenous and after intracoronary administration in anaesthetized pigs.
Introduction
Diverse pharmacological treatments can have equal hypotensive effects in essential hypertension, despite apparently distinct modes of action (e.g. Ca2 + antagonism, angiotensin converting enzyme-inhibition). Recently, a new class of vasodilators, the potassium channel activators, has been introduced. These drugs cause hyperpolarization of the membranes of vascular smooth muscle cells, which reduces the availability of Ca2+ and thereby attenuates contraction . Furthermore, the cells become less sensitive to depolarizing stimuli (Clapham & Wilson, 1987; Cook, 1988; 1989) . The vasodilator and cardiac effects of drugs like cromakalim Weir & Weston, 1988; Cook & Hof, 1988) and pinacidil (Bray et al., 1987) and also the cardiac effects of nicorandil (Weir & Weston, 1988) are mediated by opening of adenosine 5'-triphosphate (ATP)-dependent potassium channels. These potassium channels have been shown to be important in mediating the hypoxic dilatation of coronary arteries (Daut et al., 1990) .
Cromakalim, at doses causing similar decreases in arterial blood pressure as nifedipine, exhibits a vasodilator profile which is clearly different from that of the calcium antagonists (Buckingham et al., 1986) . The aim of the present study was to investigate the systemic haemodynamics and the distribution of cardiac output (radioactive microsphere technique) in response to intravenous infusions of EMD 52692 in the anaesthetized pig. EMD 52692 (Figure 1 ), a novel benzopyran derivative, structurally identical to SR 44866 (Findlay et al., 1989) , has been shown to hyperpolarize smooth muscle cells, which has been attributed to activation of ATP-dependent potassium channels (Findlay et al., 1989; De Peyer et al., 1989; Gericke et al., 1989 Ltd, 1990 effects, we also studied the effects of EMD 52692 on myocardial performance after intracoronary infusion of the compound.
Methods

General
After an overnight fast, cross-bred Landrace x Yorkshire pigs of either sex (22-28 kg, n = 29) were sedated with 120mg azaperone (Stresnil) i.m., anaesthetized with 150mg metomidate (Hypnodil) i.v., intubated and connected to a ventilator for intermittent positive pressure ventilation with a mixture Of 02 and N20 (1:2, v/v). Respiratory rate and tidal volume were set to keep arterial blood gases within the normal range: 7.41 < pH < 7.44; 42mmHg < Pco2 < 45 mmHg and 130mmHg < Po2 < 170 mmHg. 7F catheters were placed in the superior caval vein for administration of 160mg kg1 achloralose followed by an infusion of a low dose of sodium pentobarbitone (5 mgkg-h-1); for administration of the muscle relaxant pancuronium bromide (4mg) prior to thoracotomy; and for administration of haemaccel (Behringwerke A.G., Marburg, F.R.G.) to replace blood loss. Catheters were also positioned in the descending aorta for withdrawal of blood samples and measurement of central aortic blood pressure. A micromanometer-tipped catheter (7F Millar), inserted via the left carotid artery, was used to measure left ventricular pressure and its first derivative (LV dP/dt). After thoracotomy, an electromagnetic flow probe (Skalar, Delft, The Netherlands) was placed around the ascending aorta, while the great cardiac vein was cannulated for collection of blood in which the haemoglobin concentration and 02-saturation were determinedQ (OSM2, Radiometer, Copenhagen, Denmark). In 15 of the animals the proximal left anterior descending coronary artery was dissected free for placement of an electromagnetic flow probe around the vessel, while a cannula (outer diameter 0.8 mm) was inserted for intracoronary infusions of EMD 52692.
Regional bloodflows
In order to determine regional blood flows, the left atrial appendage was cannulated for injection of a batch of 1-2 x 106 carbonized plastic microspheres [15 + 1 pm (s.d.) in diameter] labelled with either "Sc, 95Nb, 103Ru, 113Sn or 141Ce. Fifteen s before the injection of microspheres, blood was withdrawn from a femoral artery at a rate of 10ml min 1 until 60-65s after completion of the injection of the microspheres. At the end of each experiment in which the animals received intracoronary infusions of either EMD 52692 or its solvent (see below), the area perfused by the left anterior descending coronary artery was identified by intracoronary injection of patent blue violet (Sigma, St. Louis, MO, U.S.A.) .
All the animals were killed with an overdose of sodium pentobarbitone and from the i.v. treated animals (see below) various organs (adrenals, bladder, stomach, small intestine, brains and kidneys) and tissues (abdominal skin, different muscle groups) were excised, weighed and put into vials. In the animals treated with intracoronary infusions only the heart was excised. The hearts were fixed in formaldehyde (10% v/v) and 48 h later divided into atria and right and left ventricle. The myocardium of the left ventricle was divided into three layers of equal thickness: subepicardium, mesocardium and subendocardium. The kidneys were divided into medulla and three cortical layers of equal thickness. The cerebral hemispheres, cerebellum, diencephalon and brain stem were separated in order to obtain regional blood flow data from the different parts of the brain.
The radioactivity was counted and the amount of blood flow to the various tissues (Qt) Qart is the rate of withdrawal of the blood sample. Although the lungs receive microspheres via both peripheral arteriovenous anastomoses and bronchial arteries, the contribution via the latter route appears to be only about 1% of cardiac output (Baile et al., 1982) . Thus, the values for the lung blood flow can be used as an index of the arteriovenous anastomotic flow (i.e. non-nutrient part of the cardiac output). The nutrient part of the cardiac output was calculated by subtracting 'lung flow' from the cardiac output. All regional vascular conductances were calculated as the ratio between Qt.5 and the mean arterial blood pressure. Full details of the procedures and the calculation of flow data using this technique have been described earlier (Saxena et al., 1980) .
Myocardial oxygen consumption and contractilefunction
Myocardial 02-consumption (MVO2) was calculated as the product of coronary blood flow and the difference in the°2 contents of the arterial and coronary venous blood. Regional myocardial segment length shortening was measured with sonomicrometry (Triton Technology Inc., San Diego, CA, U.S.A.) by a pair of ultrasonic crystals implanted approximately 10-15 mm apart in the subepicardial layers (during intracoronary infusions) or the midmyocardial layers (during the intravenous infusions), oriented parallel to the short axis (Freeman et al., 1985) . In order to differentiate between the effect of EMD 52692 on the different layers of the myocardium, another pair of crystals was also implanted in the subendocardial layers of the animals which received the intracoronary infusions of EMD 52692. At the end of each experiment the position of the subendocardial crystals was confirmed. From the tracings, segment length shortening (SLS) was calculated as: SLS (%)=100 x (EDL -ESL)/ EDL, in which EDL and ESL are the segment length at enddiastole and end-systole, respectively.
Experimental protocols
Four consecutive 10min intravenous infusions of EMD 52692 (0.15, 0.3, 0.6 and 1.2pg kg-min-t; total cumulative doses of 1.5, 4.5, 10.5 and 22.5 pgkg'-1; n = 7) or equal volumes of the solvent (n = 7) or four consecutive 10min intracoronary infusions of EMD 52692 (0.0095, 0.019, 0.0375 and 0.075 ug kg-min-; total cumulative doses of 0.10, 0.29, 0.66 and 1.41 pg kg-1; n = 7) or equal volumes of the solvent (n = 8) were administered. Systemic haemodynamics, regional myocardial function and the distribution of coronary blood flow were determined in all four series of experiments, but the distribution of cardiac output was only determined during the intravenous infusions of EMD 52692 and its solvent.
Determination of EMD 52692 plasma concentrations At the end of each infusion step blood samples (5 ml) were collected in heparinized tubes for the determination of plasma levels of EMD 52692. The blood samples were centrifuged at 1500 g at 0°C for 10 min and the plasma (2-3 ml) was stored at -80°C until further analysis. Known (v/v) polyethylene glycol for the two highest (0.60 and 1.20 pgkg-1min-1) doses and subsequently further diluted with NaCi (0.9%) to give the two lower (0.15 and 0.301ugkg-min-1) doses. The infusion rate was 1mlmin-1 for the lowest and the third, and 2mlmin-1 for the second and the highest dose. For the intracoronary infusions EMD 52692 was dissolved in 1% (v/v) polyethylene glycol and the required doses were reached by adjusting the infusion rate (from 0.25 ml min 1 to 2 ml min1).
Statistical evaluation
All data are presented as the arithmetic mean + s.e.mean. The significance of the effects of the solvent or EMD 52692 on the different variables was evaluated by Duncan's new-multiple range-test once an analysis of variance (randomized block design) had revealed that the samples represented different populations. Statistical significance was defined as P < 0.05 (two-tailed).
Results
Intravenous infusions ofEMD 52692
Plasma concentrations of EMD 52692 As the infusion rates (0.15, 0.30, 0.75 and 1.5,ugkg-minF1) of EMD 52692 were increased, the arterial plasma concentrations reached levels of 5.9 ± 0.5, 14.6 + 1.1, 30.8 ± 1.1 and 62.5 ± 2.3,ugI1, respectively.
Systemic haemodynamics No significant changes occurred during infusion of the solvent in any of the systemic haemodynamic variables (Table 1) . EMD 52692 lowered the arterial blood pressure dose-dependently (by 51% with the highest dose). This fall in arterial blood pressure was caused by systemic vasodilatation (fall in systemic vascular resistance of 52%) as cardiac output was not affected. Cardiac output was maintained, but stroke volume decreased (by up to 30%, P < 0.05), most likely secondary to the fall in left ventricular filling pressure (from 6 ± 1 mmHg to 3 + 1 mmHg, P < 0.05).
Heart rate increased dose-dependently from 103 + 7 beats min1 to 151 + 13 beats min1l (P < 0.05) with the highest dose. LVdP/dtn,,x was not affected.
Left ventricular blood flow and performance The solvent had no effect on the transmural blood flow and its distribution over the subendocardial and the subepicardial layers or on the Vasodilatation occurred in all layers of the myocardium as indicated by an increase in vascular conductance. The increase in the subepicardium (by up to 268 ± 41%) was more pronounced than the increase (by up to 65 + 16%) in the subendocardium ( Figure 2 ). In the solvent-treated animals there was a minor narrowing of the difference in the 02 contents of the arterial and coronary venous blood (5%, P < 0.05), reflected by the small increase (from 20 ± 1% to 24 + 2%) in the O2-saturation in the great cardiac vein (Figure 3 ). With EMD 52692, the decrease (35% after the highest infusion rate) in O2-extraction was considerably large as the coronary venous O2-saturation almost tripled (from 17 + 1% to 45 + 5% with the highest 
Distribution ofcardiac output
Fractionation of cardiac output into arteriovenous anastomotic and capillary flows In anaesthetized animals a large fraction of the cardiac output is shunted through arteriovenous anastomoses (Kaihara et al., 1968; Van Woerkens et al., 1990) and without affecting total cardiac output, antihypertensive drugs may affect this non-nutritional flow differently (Hof & Hof, 1989) . Figure 4 illustrates that, under baseline conditions, in both groups approximately 40% of the cardiac output was shunted through arteriovenous anastomoses. This fraction did not change during infusion of the solvent. Although EMD 52692 did not affect cardiac output, there was a redistribution in favour of the capillary flow, which increased to 85% of cardiac output after the highest dose.
Regional blood flows Blood flow to the atria and the right ventricle increased dose-dependently during the EMD 52692 infusions ( Figure 5 ). Taking into account the decrease in perfusion pressure it is clear that the increments in vascular conductance were even more pronounced ( Figure 5 ). EMD 52692 caused pronounced increases in total cerebral blood flow (32 + 3, 34 + 2, 43 + 3, 66 + 7 and 69 + 7mlmin-1OOg-1 at baseline and after 1.5, 4.5, 10.5 and 22.5 ug kg-1, respectively). Although flow to all parts of the brain increased (Figure 6 ), the increase was more pronounced in the brain stem (216 + 24%) and diencephalon (178 + 40%) than in the cerebellum (113 ± 14%) and the hemispheres (100 + 10%). The increases in regional conductances were even more impressive than the increases in flow (Figure 6 ). Total renal blood flow remained constant with the two lowest doses, but decreased by 43 + 7% after infusion of the highest dose (Table 2 ). Further analysis revealed that this was predominantly due to a dose-dependent decrease in glomerular blood flow of the outer cortex, as the glomerular blood flow of the inner cortex decreased only slightly and flow to the medulla even increased ( Table 2 ). The decreases in flow were secondary to the fall in arterial blood pressure, as total renal conductance increased significantly by as much as cortex and the medulla were not observed in the outer cortex (Table 2) .
Flow to a number of other organs was well maintained (Table 3) . Increases were observed in flow to the small intestine (by 81 + 19% with the highest dose, P < 0.05) and the adrenals (by up to 38 + 15%, P <0.05). Since the fall in arterial perfusion pressure outweighed the decrease in flow, vascular conductance was increased in all these organs (Table  3) .
The blood flow to eight different muscle groups was measured, of which only flow to the M. sternocleidomastoideus increased from 5.6 ± 0.7mlmin-1 100g-1 at baseline to 12.4 + 2.7 ml min 1 (P < 0.05), with the highest dose. Flow to all the other muscles (M. iliopsoas, pars costalis diaphragmatis, M. pectoralis, M. erector spinae, M. gluteus, M. masseter and the M. rectus abdominis) remained constant (baseline values between 2 and 6 mlmin-1 100-1). Vasodilatation occurred in all muscle groups as vascular conductance had increased 2 to 5 fold after infusion of the highest dose.
Intracoronary infusions ofEMD 52692
Systemic haemodynamics No arrhythmias were observed during infusions of either the solvent or EMD 52692. Infusion of the solvent had no effect on systemic haemodynamics (Table 4) . During infusion of the lowest two doses of EMD 52692 the only change was a 5% increase in heart rate. With the higher infusion rates there was a further increase in heart rate (by up to 22 + 4%) and a 16 + 3% decrease in mean arterial blood pressure, due to peripheral vasodilatation (decrease in systemic vascular resistance of 16 + 4%). Cardiac output and left ventricular filling pressure did not change, while LV dP/dt,,,.. showed an increase (24 + 8%, P < 0.05) after infusion of the highest dose. Data are mean + s.e.mean; n = 8 for the solvent-treated and n = 7 for the EMD 52692-treated animals. HR = heart rate (beats minm l); MAP = mean arterial blood pressure ( Myocardial performance Intracoronary infusions of the solvent had no effect on myocardial perfusion (Figure 7) . A representative example of the effects of EMD 52692 is presented in Figure 8 , which clearly shows the EMD 52692-induced increases in coronary blood flow. EMD 52692 dosedependently increased transmural blood flow of the myocard- ium perfused by the left anterior descending coronary artery by up to 128% (Figure 7) . Although all layers benefitted from the increase in transmural flow, the increments in the subepicardium (242 + 55 ml min 100 g -1) were considerably larger than in the subendocardium (140 + 46 ml min-I 100g-1). There were no significant changes in myocardial blood flow (Figure 7 ) or vascular conductance (not shown) of the posterior wall of the left ventricle (the myocardium not perfused by the left anterior descending coronary artery).
The solvent had no effect on myocardial O2-consumption (499 39, 486 + 41, 593 + 29, 529 + 52, 523 + 59pumol min 1 00 g -at baseline and after 10, 20, 30 and 40min of solvent infusion, respectively) or on regional subendo-and subepicardial segment length shortening (Table 5) . Subendocardial segment length shortening decreased from 18.2 ± 1.6% to 16.8 + 1.0% with the highest dose of EMD 52692 P < 0.05). Subepicardial segment length shortening tended to increase, but the increments did not reach levels of significance (Table 5) . Myocardial 02-consumption of the LADCA-perfused myocardium was not affected by the drug (542 + 43, 522 + 26, 560+33, 618+ 17 and 521+46pmolmin-1 100g1' at baseline and after 0.095, 0.29, 0.66 and 1.41 zgkg-1, respectively).
Discussion
In the present study the plasma levels of EMD 52692 ranged from 5.1 to 62jug I1-. This range compares well with the effective in vitro concentrations described by De Peyer and colleagues (1989) . In this last study the ECjo of EMD 52692 to hyperpolarize the membrane of the vascular smooth muscle cells of porcine coronary arteries was 0.6-1 x 10-0M, which corresponds with a concentration of 16-26pg 1-1.
EMD 52692 is a potent systemic vasodilator. Its potency exceeds that of nicorandil, tested in the same model by a factor of 100 (Verdouw et al., 1987 dogs than cromakalim and pinacidil, respectively (Schliep et al., 1989) , two other compounds of which the pharmacological actions have been ascribed to potassium channel opening Bray et al., 1987; Weir & Weston, 1988) . The potency of EMD 52692 to dilate the systemic vascular bed, also compares favourably with that of the most potent representatives of the dihydropyridine calcium antagonists such as nisoldipine (Duncker et al., 1986) and elgodipine (Sassen et al., 1990) . Contraction of vascular smooth muscle cells in capacitance vessels depends on a rise in intracellular free calcium, mediated by activation of receptor-operated rather than voltageoperated events (Bolton, 1979) . Webb and colleagues (1989) found that cromakalim produced dose-dependent dilatation of forearm resistance vessels, but did not dilate dorsal hand veins preconstricted with noradrenaline and concluded that this potassium channel activator was arterioselective. However, we observed at similar increments in heart rate (e.g. compare the second infusion rate of the intravenous and the highest infusion rate of the intracoronary experiments), that left ventricular end-diastolic pressure decreased after the intravenous, but not after the intracoronary infusions. The dose-dependent decrease in left ventricular filling pressure during the intravenous infusions can therefore not solely be attributed to the tachycardia and EMD 52692 most likely caused some venodilatation during the intravenous infusions.
The increase in heart rate, which has also been demonstrated for cromakalim (Buckingham et al., 1986) , was most likely a reflex-mediated response, and is a common feature of acute administration of vasodilators. Despite the tachycardia, cardiac output did-not increase. We have shown that in the same model vasodilators such as nisoldipine (Duncker et al., 1986) and nicorandil (Verdouw et al., 1987) (Verdouw et al., 1987; Duncker et al., 1988) , indicating that the anaesthesia may have attenuated the reflex-mediated responses.
Potassium channel activators have potentially negative inotropic properties (Yanagisawa et al., 1988) , although the selectivity for vascular smooth muscle outweighs that for the myocardium (Cohen & Colbert, 1986; Longman et al., 1988; Gotanda et al., 1988) . SR 44866, a compound which is structurally identical to EMD 52692 has been shown to have inhibitory effects on the electrical and mechanical activity of cardiac muscle (Findlay et al., 1989) In anaesthetized animals a substantial fraction of the cardiac output is shunted through arteriovenous anastomoses (Kaihara et al., 1968; Saxena & Verdouw, 1985) , which is reflected by the large entrapment of the microspheres in the lungs after induction of anaesthesia (Van Woerkens et al., 1990) . Figure 4 shows that although cardiac output did not change, the nutritional fraction increased with increasing doses of EMD 52692. This increase was most prominent in the brain, adrenals and small intestine, but absent in skeletal muscle. This study therefore confirms earlier investigations that potassium channel activators at equihypotensive dosages have a different vasodilator profile than for instance the calcium antagonists (Duncker et al., 1986; Buckingham et al., 1986; Sassen et al., 1990) . When comparing the vasodilator profile of EMD 52692 with two compounds that were tested in the same model, nicorandil (Verdouw et al., 1987) and elgodipine (Sassen et al., 1990 ), a calcium antagonist very similar to nisoldipine (Duncker et al., 1986 ), it appears that EMD 52692 closely resembles nicorandil; similar increases in adrenal, cerebral, left ventricular and intestinal blood flow occurred while no effect on skeletal muscle blood flow at comparable increases in systemic vascular conductance was observed. Furthermore, it can be concluded that EMD 52692 dilates cerebral and adrenal vascular beds much more potently than elgodipine, but that the increase in vascular conductance of skeletal muscle by the potassium channel activator is less than by the calcium antagonist. Of interest is that the initial vasodilatation in the kidneys, as observed with elgodipine and EMD 52692 was followed by a decrease with the highest dose although systemic vascular conductance still increased. These vascular responses in the kidneys differed markedly in the inner and outer cortex and the medulla, as a result of which blood flow was redistributed away from the outer to the inner layers. A similar redistribution of renal flow during hypotension has been obtained by other investigators (see Carriere, 1975) and may thus be a perfusion pressuredependent response rather than a direct drug action. The reduction in cortical glomerular blood flow might serve to enhance fluid retention to counterbalance the severe hypotension (Wright & Briggs, 1979) .
Only a few studies have described the vasodilator profiles of other potassium channel activators (Arrigoni-Martelli et al., 1980; Buckingham et al., 1986; Cook & Hof, 1988) . Cook & Hof (1988) ments the increase in 02-demand caused by the increase in heart rate was fully compensated for by the decrease in arterial blood pressure. The increase in flow has therefore no metabolic origin and indicates that the coronary blood flow response is the result of a direct action of the drug on the coronary vascular bed. The finding that with the intravenous infusions the increase in flow was almost exclusively confined to the subepicardial layers is not surprising in view of the tachycardia and hypotension (Domenech & Goich, 1976) ; this has also been demonstrated for nicorandil (Verdouw et al., 1987) . Chronic treatment often leads to a reduction of the reflex tachycardia (Kiowski et al., 1983) . If the coronary vasodilator action were to be sustained with chronic treatment, the lower heart rate would most likely not only lower myocardial 02-demand but also shift coronary blood flow in favour of the subendocardial layers.
In conclusion, EMD 52692 is a potent arterial vasodilator with particularly pronounced effects on the cerebral vasculature. At doses exceeding the clinically relevant range, negative inotropic actions were not observed. The cardiovascular profile suggests that the drug may be useful in the treatment of hypertension and, in view of the lack of negative inotropic actions, of heart failure. The pronounced coronary, cerebral and mesenteric vasodilatation warrants investigations with this compound in syndromes of myocardial, cerebral and intestinal ischaemia.
